# A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer

> **NCT00355238** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 137 (actual)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** brivanib (active)

## Key facts

- **NCT ID:** NCT00355238
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12-31
- **Primary completion:** 2010-04-30
- **Final completion:** 2010-04-30
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2023-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00355238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00355238, "A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00355238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*